Hematology

A phase 2 study found the EAP regimen achieved optimal stem cell mobilization in most patients with multiple myeloma or lymphoma, with low plerixafor need.

Nipocalimab-aahu (IMAAVY) is now approved for wAIHA, based on Phase 2/3 ENERGY trial data showing durable hemoglobin response.

New research links germline genetic variants to CAR T cell toxicity risk and expansion in lymphoma patients treated with axi-cel.

Hematology in July 2026: FDA priority review for Agios' mitapivat in sickle cell disease, plus Orca-T's approval for GVHD-free survival.

Stay updated with the latest healthcare breakthroughs, including phase 3 plozasiran data in hypertriglyceridemia and the FDA approval of Furoscix ReadyFlow.

Stay updated with the latest healthcare breakthroughs, including phase 3 plozasiran data in hypertriglyceridemia, the FDA approval of Furoscix ReadyFlow, and more.

Agios ends tebapivat development in sickle cell disease after phase 2 results show no differentiated benefit.

Wendy Stock, MD, on the recent FDA approval of Orca-T, a precision-engineered cell therapy for allogeneic transplant in adults with hematological malignancies

FDA grants Priority Review to Agios’ mitapivat sNDA for sickle cell disease, with a PDUFA date set for November 1, 2026.

Exagamglogene autotemcel (Casgevy) is now the first CRISPR-based gene-editing therapy to reach this age group in either condition.

Stay updated with the latest healthcare breakthroughs, including FDA submissions and new cardiology guidelines.

Catch up on the hematology news and data you missed from April 2026.

Stay updated with the latest healthcare breakthroughs, including FDA actions and new topline clinical trial data, in this week’s essential news roundup.

Etavopivat reduced VOC events by 27% and improved hemoglobin response in the phase 3 HIBISCUS trial in sickle cell disease.

Catch up on the hematology headlines you missed in March 2026.

Stay updated with the latest healthcare breakthroughs, including FDA actions and comparative weight loss drug data, in this week’s essential news roundup.

ASH publishes 33 clinical recommendations and 4 good practice statements for the diagnosis and treatment of severe and very severe acquired aplastic anemia.

Rapid NGS and streamlined workflows are critical to delivering timely, actionable genomic insights in blood cancers, but access, reimbursement, and expertise gaps persist.

In the first study of its kind, researchers found that physicians treating sickle cell disease experience burnout at a rate of 60% — driven not by personal factors, but by systemic ones.

Stay updated with the latest healthcare breakthroughs, FDA actions, and new trial data, in this week’s essential news roundup.

In February 2026, rusfertide garnered priority review, ASH published new guidelines, and luspatercept mets its primary endpoint in a phase 2a trial.

The FDA granted Priority Review and accepted a New Drug Application for rusfertide to treat adults with polycythemia vera.